News >

Tumor Treating Fields Show Promise in Ovarian Cancer

Audrey Sternberg
Published: Tuesday, Aug 07, 2018

Ignace Vergote

Ignace Vergote

In combination with weekly paclitaxel (Taxol), tumor treating fields (TTF), an antimitotic therapy that delivers continuous low-intensity electrical fields to the tumor region, has been found safe in platinum-resistant ovarian cancer, according to results of INNOVATE (NCT02244502), a phase II single-arm trial.1

With a primary endpoint of safety, INNOVATE found no serious adverse events (AEs) from TTF, and investigators said the combination with weekly paclitaxel was well tolerated with encouraging response and survival data.

Based on these results, investigators will move forward with INNOVATE-3, a prospective open-label study that will randomize 540 patients with recurrent, platinum-resistant ovarian cancer to weekly paclitaxel alone or weekly paclitaxel in combination with TTF tuned to 200 kHz until progression.2

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication